Utilizzo di acido zoledronico in pazienti con metastasi ossee da carcinoma prostatico: controllo del dolore e delle complicanze muscolo-scheletriche.

Translated title of the contribution: [Use of zoledronic acid in patients with prostate cancer bone metastases: control of pain and musculoskeletal complications].

Stefano Paparella, Elisabetta Finkelberg, Daniela Varisco, Elena Tondelli, Francesco Rocco

Research output: Contribution to journalArticle

Abstract

Background. Patients suffering from prostatic carcinoma are at high risk of having bone complications because of the metastatic progression of the disease to the skeleton and the consequences of androgenic deprivation. Zoledronic acid is a potent inhibitor of the bone resorption mediated by the osteoclasts, and is the only bisphosphonate whose capacity of reducing significantly the skeleton morbidity in patients with bone metastases is statistically proved. Methods. To attest tolerability and efficacy of zoledronic acid in preventing unfavorable skeletal events and in reducing osteomuscular pain, 25 patients - aged 75 years, suffering from hormone-responsive prostatic carcinoma under hormonal therapy with bone metastases, have been followed and subjected to IV monthly infusion of 4 mg zoledronic acid for 12 consecutive months, associated to daily intake of calcium and multivitamin supplementations. Results. At the end of the study, a sensible improvement in their clinical conditions and in their perception of the pain has been recorded in 23 patients and valued through a set of questions (Brief Pain Inventory). Conclusions. Zoledronic acid is therefore confirmed to be an effective medicine in preventing the skeleton complications and in controlling the painful symptoms in patients suffering from prostatic carcinoma with bone metastases.

Translated title of the contribution[Use of zoledronic acid in patients with prostate cancer bone metastases: control of pain and musculoskeletal complications].
Original languageItalian
Pages (from-to)300-304
Number of pages5
JournalUrologia
Volume78
Issue number4
DOIs
Publication statusPublished - Oct 2011

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of '[Use of zoledronic acid in patients with prostate cancer bone metastases: control of pain and musculoskeletal complications].'. Together they form a unique fingerprint.

  • Cite this